Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
01 Maio 2024 - 8:30AM
Business Wire
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in
immunology-based therapies for cancer, received notice from NASDAQ
on April 30, 2024, that the Company has regained compliance with
the $1.00 minimum bid price requirement set forth in NASDAQ Listing
Rule 5550(a)(2). Accordingly, the Company now satisfies all
requirements for continued listing on the NASDAQ Capital Market and
the matter is now closed.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and
infectious diseases with a comprehensive pipeline of immunological
agents. The company’s mission is to expand patient populations
benefiting from cancer immunotherapy through combination
approaches, using a broad repertoire of antibody therapeutics,
adoptive cell therapies (through MiNK Therapeutics) and adjuvants
(through SaponiQx). Agenus is headquartered in Lexington, MA. For
more information, visit www.agenusbio.com or @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and social media channels.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240501950583/en/
Investors 917-362-1370
investor@agenusbio.com
Media 917-362-1370
communications@agenusbio.com
Agenus (NASDAQ:AGEN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Agenus (NASDAQ:AGEN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024